156 results
Page 4 of 8
8-K
EX-99.1
mnjtvvw1o f63
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am
8-K
EX-99.1
sek84q4c2e 4oglgyn9e
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
EX-10.1
ydxwr rg4ax4i
16 Feb 21
Entry into a Material Definitive Agreement
7:10am
8-K
EX-10.1
9sgkx
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
EX-99.1
xg93j
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
EX-99.2
a67sm3f026j48 w0
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
llpy772hsvul
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-10.1
j7pkjangm gfjg6r
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
EX-99.1
ptkpjs0cb4b65 vmkf5d
5 Nov 20
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
4:31pm
8-K
m2aahccfvj6x8q2f4
4 Sep 20
Entry into a Material Definitive Agreement
4:32pm
8-K
EX-99.1
6j8lh6msgzjr0315k
3 Aug 20
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
EX-99.1
p6dt1
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
8-K
EX-99.1
18uvi99
9 Apr 20
Aravive Announces Board Composition and Executive Management Transitions
4:43pm